Clinical Trial Update: Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) [Phase 3]

View source ↗

Summary

Phase 3 trial KEYNOTE-679/ECHO-302 evaluating pembrolizumab plus epacadostat versus standard of care in metastatic renal cell carcinoma has posted results (2019…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Epacadostat (epacadostat)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Incyte Corporation | Conditions: Renal Cell Carcinoma (RCC) | Phase 3 | Status: COMPLETED | Results posted: 2019-09-10